Aluminum bioavailability from foods
食物中铝的生物利用度
基本信息
- 批准号:6694057
- 负责人:
- 金额:$ 21.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-02-08 至 2007-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
There is concern about brain aluminum accumulation over the life span that might contribute to Alzheimer's disease and related neurodegenerative disorders. The overall objective of the proposed research is to test the null hypothesis that the bioavailability of Al is comparable from foods and from drinking water. If the null hypothesis is accepted the concern about Al intake for typical Americans should focus on food and not drinking water. The specific aims are to produce food products containing 26Al in the normal chemical species for these foods and determine Al oral bioavailability from these selected representative foods, compared to Al oral bioavailability from drinking water. Foods to be produced are a baked good and a processed cheese, in which 26Al will be incorporated during food production, and spinach and tea, in which 26Al will be incorporated during their hydroponic production. Al bioavailability will be determined from the area under the serum 26Al concentration x time curve after bolus administration of the 26Al-containing food compared to the equivalent term obtained from serum 27Al concentration produced by continuous intravenous 27Al infusion throughout the study. 26Al will be analyzed by accelerator mass spectroscopy; 27Al by atomic absorption spectroscopy. It is hypothesized that oral Al bioavailability from food will be less than from water, due to Al binding to food components that inhibit its absorption. The results will resolve the controversy whether drinking water contributes a significant amount of the Al that is absorbed by the human. The results will suggest whether health-based standards to regulate Al in drinking water should be considered by regulatory agencies or whether reduction of absorbed Al in the human can be more effectively achieved by reducing Al in foods.
人们担心,人的一生中大脑铝的积累可能会导致阿尔茨海默氏症和相关的神经退行性疾病。这项拟议研究的总体目标是检验零假设,即铝的生物可利用性与食物和饮用水相当。如果零假设被接受,对典型美国人铝摄入量的担忧应该集中在食物上,而不是饮用水上。其具体目标是为这些食品生产含26Al的食品,并确定这些选定的代表性食品中铝的口服生物利用度,与饮用水中铝的口服生物利用度进行比较。将生产的食品是烘焙食品和加工奶酪,其中26Al将在食品生产中加入,以及菠菜和茶,其中26Al将在水培生产中加入。在整个研究过程中,铝的生物利用度将从口服含26Al食物后的血清26Al浓度×时间曲线下的面积与通过持续静脉注射27Al产生的血清27Al浓度获得的等效项进行比较。用加速器质谱仪分析26Al,用原子吸收光谱分析27Al。据推测,由于铝与抑制其吸收的食物成分结合,来自食物的口服铝的生物利用度将低于从水中获得的铝。这一结果将解决饮用水是否对人体吸收的铝有很大贡献的争议。这些结果将表明,监管机构是否应该考虑以健康为基础的标准来管理饮用水中的铝,或者是否可以通过减少食品中的铝来更有效地减少人体吸收的铝。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Aluminum bioavailability from tea infusion.
- DOI:10.1016/j.fct.2008.09.041
- 发表时间:2008-12
- 期刊:
- 影响因子:4.3
- 作者:Yokel, Robert A.;Florence, Rebecca L.
- 通讯作者:Florence, Rebecca L.
Aluminum bioavailability from basic sodium aluminum phosphate, an approved food additive emulsifying agent, incorporated in cheese.
- DOI:10.1016/j.fct.2008.03.004
- 发表时间:2008-06
- 期刊:
- 影响因子:0
- 作者:R. Yokel;C. L. Hicks;Rebecca L. Florence
- 通讯作者:R. Yokel;C. L. Hicks;Rebecca L. Florence
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert Allen Yokel其他文献
Robert Allen Yokel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert Allen Yokel', 18)}}的其他基金
Reconciling Nanoceria's Jekyll and Hyde Reputation Toward Safer Nanotherapy
调和 Nanoceria 的 Jekyll 和 Hyde 声誉以实现更安全的纳米疗法
- 批准号:
9303423 - 财政年份:2015
- 资助金额:
$ 21.95万 - 项目类别:
A device containing an immobilized chelator to remove aluminum from total parente
一种含有固定螯合剂的装置,用于去除总母体中的铝
- 批准号:
7801648 - 财政年份:2008
- 资助金额:
$ 21.95万 - 项目类别:
A device containing an immobilized chelator to remove aluminum from total parente
一种含有固定螯合剂的装置,用于去除总母体中的铝
- 批准号:
8079641 - 财政年份:2008
- 资助金额:
$ 21.95万 - 项目类别:
A device containing immobilized chelator to remove aluminum from TPN solutions
一种含有固定化螯合剂的装置,用于从 TPN 溶液中去除铝
- 批准号:
7393043 - 财政年份:2008
- 资助金额:
$ 21.95万 - 项目类别:
THE MONOCARBOXYLATE TRANSPORTER IN DETOXIFICATION
解毒中的单羧酸转运蛋白
- 批准号:
6140018 - 财政年份:2001
- 资助金额:
$ 21.95万 - 项目类别:
ALUMINUM TOXICITY--CHELATOR IDENTIFICATION AND SAFETY
铝毒性--螯合剂的鉴定和安全性
- 批准号:
3252747 - 财政年份:1991
- 资助金额:
$ 21.95万 - 项目类别:
ALUMINUM TOXICITY--CHELATOR IDENTIFICATION AND SAFETY
铝毒性--螯合剂的鉴定和安全性
- 批准号:
2153710 - 财政年份:1991
- 资助金额:
$ 21.95万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 21.95万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 21.95万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 21.95万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 21.95万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 21.95万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 21.95万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 21.95万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 21.95万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 21.95万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 21.95万 - 项目类别:














{{item.name}}会员




